Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
SPRY
vs
S&P 500
SPRY
S&P 500
Over the past 12 months, SPRY has underperformed S&P 500, delivering a return of -64% compared to S&P 500's +16% growth.
Stocks Performance
SPRY vs S&P 500
Performance Gap
SPRY vs S&P 500
Performance By Year
SPRY vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
ARS Pharmaceuticals Inc
Glance View
ARS Pharmaceuticals makes neffy, a needle-free epinephrine nasal spray used for emergency treatment of severe allergic reactions, including anaphylaxis. The company focuses on giving patients and caregivers a simpler alternative to the traditional epinephrine auto-injector, especially in situations where speed and ease of use matter most. Its core job is to turn an emergency drug into a form that is easier to carry and use outside a hospital. The main customers are patients at risk of severe allergies, along with parents, caregivers, doctors, and pharmacies that help prescribe and dispense the product. ARS Pharmaceuticals makes money by selling neffy through the prescription drug channel, with demand driven by allergy specialists, primary care doctors, and patients who need rescue treatment they can use quickly in an emergency. It sits in the branded allergy and emergency medicine market, where product design and patient convenience are a big part of the value. What makes the business different is that it is built around a single, very specific use case: replacing the needle-based epinephrine shot with a nasal spray. That gives it a clear role in the value chain as a drug developer and commercial seller rather than a broad pharmaceutical company. Its success depends on adoption of neffy by prescribers, pharmacists, insurers, and patients who want an easier way to carry emergency epinephrine.